NDAINHALATIONPOWDER
Approved
Dec 2013
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
4/8 — Partial
Drug data last refreshed 16h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANORO ELLIPTA is a dual-agent combination inhaled powder containing umeclidinium bromide (long-acting muscarinic antagonist) and vilanterol trifenatate (long-acting beta-2 agonist) for maintenance treatment of chronic obstructive pulmonary disease (COPD). The combination targets two distinct pathways to provide sustained bronchodilation and improve lung function in COPD patients.
$873MPart D
Peak4.2 years to LOEPeak-stage product with $873M in Part D spending and 1.39M claims (2023) indicates mature franchise requiring commercial optimization and competitive defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on ANORO ELLIPTA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.